A clear, educational guide to Pina Colada’s reported genetics, tropical terpene profile, product formats, cultivation considerations, and DMV context.

Cultivators in Nebraska urge state officials to revise testing rules, fee structures, and doctor protections as medical cannabis regulations develop in 2026.

Georgia’s medical cannabis program is expanding even as state regulators wait for input from the DEA. Here’s why it matters and what DMV readers should watch.

Marijuana Venture highlights a new Blackridge Intelligence report on cannabis site selection. Here’s how this affects delivery operators, retailers, and cultivators planning new locations in the DMV.

Idahoans will decide whether only lawmakers—not voters—can legalize marijuana or other psychoactive drugs. Here’s what HJR 4 does, who backs it, and why it matters beyond Idaho.

Federal cannabis rescheduling is expected to pull producers under the same GMP standards that govern other consumed products, with new equipment rules likely to follow.

Massachusetts is poised to allow cannabis lounges, becoming the first in New England to move in this direction. Here’s what we know so far—and how operators can start preparing responsibly.

High Times reports a court blocked a Trump press ban, tracing its roots to an episode involving the magazine’s founder and a pie—here’s why that media-access fight matters for cannabis policy watchers in the DMV.

A practical guide to Pave’s reported genetics, flavor, effects, product formats, testing, cultivation profile, and DMV growing considerations.

A plain‑English guide to how culture, compliance, and licensing collide in weed delivery — and what DC, Maryland, and Virginia residents should watch now.

MJBizDaily reports cannabis multistate operators have given millions to President Donald Trump’s PACs, which may fund a staunchly anti-cannabis Senate hopeful. Here’s what it could mean.

A new DEA registration pathway pulls state-licensed medical cannabis manufacturers, distributors, and labs into the federal Schedule III framework—potentially easing 280E tax pain.

High Times reports NORML’s Paul Armentano sees a two-front squeeze: GOP rollbacks in several states and Democratic tax hikes in others. Here’s what DMV consumers should watch.

A documented increase in medical cannabis authorizers and broad clinician support could reshape patient access and operator strategy. Here’s how DMV readers can think about it.

DEA adds dedicated federal registration paths for state-licensed medical marijuana manufacturers, distributors, and testing labs, expanding beyond dispensaries amid ongoing Schedule III transition.

A new op-ed spotlights how Latino and immigrant workers power cannabis cultivation and retail—and why federal immigration policy and partial rescheduling still put them at risk.

New Mexico’s Enforcement Bureau is actively investigating more than two dozen cannabis and hemp cases, including an alleged unlicensed mega-grow and unsafe hemp THC products.

As a federal hemp ban looms, MJBizDaily reports delta-8 THC could face different treatment—yet rules remain unclear. Here's what operators and DMV consumers should know now.

Gov. Maura Healey says keep cannabis legal as Massachusetts voters face a November measure to roll back adult-use sales and home grow. Here’s what’s at stake and why DMV readers should care.

DEA’s 2026 Drugs of Abuse update says no deaths from marijuana overdose and reflects federal moves toward Schedule III for certain cannabis products. Here’s what it means in practice.